Table of Contents

company-logo

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Moleculin Biotech Dividend Announcement

• Moleculin Biotech does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Moleculin Biotech dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Moleculin Biotech Dividend History

Moleculin Biotech Dividend Yield

Moleculin Biotech current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Moleculin Biotech stock? Use our calculator to estimate your expected dividend yield:

Moleculin Biotech Financial Ratios

P/E ratio-0.32
PEG ratio-0.00
P/B ratio1.28
ROE-165.56%
Payout ratio0.00%
Current ratio2.08
Quick ratio2.08
Cash Ratio1.68

Moleculin Biotech Dividend FAQ

Does Moleculin Biotech stock pay dividends?
Moleculin Biotech does not currently pay dividends to its shareholders.
Has Moleculin Biotech ever paid a dividend?
No, Moleculin Biotech has no a history of paying dividends to its shareholders. Moleculin Biotech is not known for its dividend payments.
Why doesn't Moleculin Biotech pay dividends?
There are several potential reasons why Moleculin Biotech would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Moleculin Biotech ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Moleculin Biotech has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Moleculin Biotech a dividend aristocrat?
Moleculin Biotech is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Moleculin Biotech a dividend king?
Moleculin Biotech is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Moleculin Biotech a dividend stock?
No, Moleculin Biotech is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Moleculin Biotech stocks?
To buy Moleculin Biotech you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Moleculin Biotech stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.